Philadelphia, Pennsylvania--(Newsfile Corp. - July 3, 2025) - Current CorMedix Inc. (NASDAQ: CRMD) shareholders who have held CorMedix shares since prior to October 16, 2019, can now seek corporate reforms, the return of funds spent defending litigation back to the company, and a court approved incentive award at no cost to them whatsoever. If you would like to learn more about this matter, you are encouraged to visit https://grabarlaw.com/the-latest/cormedix-shareholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085.
Why? As alleged in an underlying securities fraud class action complaint, CorMedix (NASDAQ: CRMD), via certain of its officers, made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, the Complaint alleges Defendants made material misrepresentations concerning the following: (i) deficiencies existed with respect to DefenCath's manufacturing process and/or at the facility responsible for manufacturing DefenCath; (ii) in light of the foregoing deficiencies, the FDA was unlikely to approve the DefenCath NDA for catheter-related bloodstream infections ("CRBSIs") in its present form; (iii) Defendants had downplayed the true scope of the deficiencies with DefenCath's manufacturing process and/or at the facility responsible for manufacturing DefenCath; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
On June 30, 2025, the court denied Defendants' motion to dismiss the complaint, determining that Plaintiffs had adequately alleged material misrepresentations; scienter (either (1) a motive and opportunity to commit fraud or (2) "circumstantial evidence of either reckless or conscious behavior"); and loss causation.
What You Can Do Now:Current CorMedix shareholders who have held CorMedix shares since prior to October 16, 2019, can now seek corporate reforms, the return of funds spent defending litigation back to the company, and a court approved incentive award at no cost to them whatsoever. If you would like to learn more about this matter, you are encouraged to visit https://grabarlaw.com/the-latest/cormedix-shareholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085.
#CorMedix $CRMD
Attorney Advertising Disclaimer
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/257666
